

Katia Mazzocco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5553881/publications.pdf>

Version: 2024-02-01

50
papers

1,609
citations

304743

22
h-index

302126

39
g-index

53
all docs

53
docs citations

53
times ranked

1774
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of ^{125}I -Np73 is a molecular marker for adverse outcome in neuroblastoma patients. <i>Cell Death and Differentiation</i> , 2002, 9, 246-251.	11.2	183
2	Quality Assessment of Genetic Markers Used for Therapy Stratification. <i>Journal of Clinical Oncology</i> , 2003, 21, 2077-2084.	1.6	113
3	MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.. <i>Journal of Clinical Oncology</i> , 1997, 15, 85-93.	1.6	111
4	Comprehensive Genetic and Histopathologic Study Reveals Three Types of Neuroblastoma Tumors. <i>Journal of Clinical Oncology</i> , 2001, 19, 3080-3090.	1.6	103
5	Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative) <i>Tj ETQq1 1 0.784314 rgBT4/Overlo</i>	1.4	102
6	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1084-1093.	6.3	73
7	Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 442, 555-562.	2.8	68
8	Neuroblastoma in adolescents. <i>Cancer</i> , 2006, 106, 1409-1417.	4.1	65
9	Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study. <i>Cancers</i> , 2019, 11, 1476.	3.7	43
10	Bone Marrow-Infiltrating Human Neuroblastoma Cells Express High Levels of Calprotectin and HLA-G Proteins. <i>PLoS ONE</i> , 2012, 7, e29922.	2.5	40
11	Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 20-29.	1.0	39
12	A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. <i>Clinical Cancer Research</i> , 2011, 17, 792-804.	7.0	39
13	Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. <i>British Journal of Cancer</i> , 2015, 112, 290-295.	6.4	39
14	Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells. <i>Journal of Pathology</i> , 2005, 207, 346-357.	4.5	36
15	Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. <i>American Journal of Medical Genetics Part A</i> , 2003, 118A, 309-313.	2.4	35
16	Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the <i>hMLH1</i> gene in advanced stage, high-risk, neuroblastic tumor patients. <i>International Journal of Cancer</i> , 2010, 126, 656-668.	5.1	35
17	Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. <i>Annals of Oncology</i> , 2002, 13, 956-964.	1.2	31
18	19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis. <i>Npj Genomic Medicine</i> , 2020, 5, 18.	3.8	31

#	ARTICLE	IF	CITATIONS
19	Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). <i>Journal of Clinical Oncology</i> , 2021, 39, 3377-3390.	1.6	30
20	Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. <i>British Journal of Cancer</i> , 2018, 118, 1502-1512.	6.4	28
21	Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients' survival and indicate proteins targetable at onset of disease. <i>International Journal of Cancer</i> , 2018, 143, 2525-2536.	5.1	27
22	Genetic abnormalities in adolescents and young adults with neuroblastoma: A report from the Italian Neuroblastoma Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1725-1732.	1.5	25
23	Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants. , 2021, 9, e002293.		25
24	Gene expression and protein localisation of calcyclin, a calcium-binding protein of the S-100 family in fresh neuroblastomas. <i>European Journal of Cancer</i> , 1995, 31, 499-504.	2.8	24
25	Two regions of deletion in 9p22 ¹ /4p24 in neuroblastoma are frequently observed in favorable tumors. <i>Cancer Genetics and Cytogenetics</i> , 2002, 135, 42-47.	1.0	20
26	Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome. <i>Cancer Letters</i> , 1998, 130, 83-92.	7.2	19
27	Biological and clinical role of p73 in neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 111-117.	7.2	19
28	Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization. <i>Molecular Diagnosis and Therapy</i> , 2004, 8, 93-100.	1.1	17
29	Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma. <i>European Journal of Cancer</i> , 2008, 44, 2634-2639.	2.8	17
30	<i>MDM2</i> SNP309 genotype influences survival of metastatic but not of localized neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2009, 53, 576-583.	1.5	17
31	Stage 4 neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry. <i>Italian Journal of Pediatrics</i> , 2019, 45, 8.	2.6	17
32	Evidence of apoptosis in neuroblastoma at onset and relapse. An analysis of a large series of tumors. <i>Journal of Neuro-Oncology</i> , 1997, 31, 217-223.	2.9	16
33	Identification of an AP-1-like sequence in the promoter region of calcyclin, a S-100-like gene. Enhancement of binding during retinoic acid-induced neuroblastoma cell differentiation. <i>Neuroscience Letters</i> , 1994, 181, 35-38.	2.1	15
34	Stage-independent expression and genetic analysis of p73 in neuroblastoma. <i>International Journal of Cancer</i> , 1999, 84, 365-369.	5.1	14
35	Neuroblastoma in Two Siblings Supports the Role of 1p36 Deletion in Tumor Development. <i>Cancer Genetics and Cytogenetics</i> , 1999, 109, 126-130.	1.0	13
36	Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy. <i>European Journal of Medical Genetics</i> , 2013, 56, 626-634.	1.3	12

#	ARTICLE	IF	CITATIONS
37	Neuroblastoma in the Adult. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e499-e505.	0.6	10
38	Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma. <i>Cancer Biology and Therapy</i> , 2017, 18, 285-289.	3.4	10
39	Molecular Genetics in Neuroblastoma Prognosis. <i>Children</i> , 2021, 8, 456.	1.5	10
40	Loss of heterozygosity for chromosome 1p in familial neuroblastoma. <i>European Journal of Cancer</i> , 1997, 33, 1953-1956.	2.8	9
41	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEL Biology Group on the LNESG Trials and a COG Validation Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 3685-3697.	1.6	9
42	Concomitant DDX1 and MYCN gain in neuroblastoma. <i>Cancer Letters</i> , 2007, 256, 56-63.	7.2	8
43	The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. <i>International Journal of Biological Markers</i> , 2009, 24, 119-129.	1.8	6
44	<i>MDM2</i> SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2010, 55, 267-272.	1.5	5
45	A Review of Infants With Localized Neuroblastoma That Evolve to Stage 4s Disease. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e483-e487.	0.6	5
46	Peculiar allelotype associated with susceptibility to neuroblastoma. , 1996, 17, 60-63.		4
47	Detection of MYCN Amplification and Chromosome 1p36 Loss in Neuroblastoma by cDNA Microarray Comparative Genomic Hybridization. <i>Molecular Diagnosis and Therapy</i> , 2004, 8, 93-100.	1.1	4
48	Restriction fragment length polymorphism analysis reveals different allele frequency and a linkage disequilibrium at locus D1S94 in neuroblastoma patients. <i>European Journal of Cancer</i> , 1997, 33, 1949-1952.	2.8	3
49	Simultaneous tumors: Acute myeloid leukemia infiltrating mediastinal ganglioneuroblastoma. <i>Pediatric Blood and Cancer</i> , 2011, 56, 298-300.	1.5	1
50	Oligonucleotide Array Comparative Genomic Hybridization Profiling of Neuroblastoma Tumours. <i>Cancer Genomics and Proteomics</i> , 2006, 3, 245-252.	2.0	1